Megan Seddon
@meganismofaction.bsky.social
ID Pharmacist 🦠💊🧫✨ Interested in Antimicrobial Resistance, PK/PD, Experiential PharmEd, Humanism in PharmEd, Narrative Medicine/Pharmacy. Views = my own. New handle, formerly ShorterSeddonRx
😻😻😻 So cute!!!
December 14, 2024 at 7:12 PM
😻😻😻 So cute!!!
Reposted by Megan Seddon
Adding mine in 😄 happy Caturday from Wheatley and Dewey!
December 14, 2024 at 7:10 PM
Adding mine in 😄 happy Caturday from Wheatley and Dewey!
There are so many awesome studies in this area - what are some of your favorites?
December 2, 2024 at 6:26 PM
There are so many awesome studies in this area - what are some of your favorites?
Hopefully these data will help reframe the risk-benefit ratio of ASB treatment. Evidence suggests risks of not treating are less than feared & perhaps treating may actually increase risk of subsequent symptomatic UTI by killing off colonizing ASB strains which may have a protective role. 10/10 🔚
December 2, 2024 at 6:26 PM
Hopefully these data will help reframe the risk-benefit ratio of ASB treatment. Evidence suggests risks of not treating are less than feared & perhaps treating may actually increase risk of subsequent symptomatic UTI by killing off colonizing ASB strains which may have a protective role. 10/10 🔚
Perhaps in the future we will be able to distinguish colonizing ASB strains from uropathogenic strains of bacteria. 9/n
pubmed.ncbi.nlm.nih.gov/31794727/
pubmed.ncbi.nlm.nih.gov/31794727/
Defining a Molecular Signature for Uropathogenic versus Urocolonizing Escherichia coli: The Status of the Field and New Clinical Opportunities - PubMed
Urinary tract infections (UTIs) represent a major burden across the population, although key facets of their pathophysiology and host interaction remain unclear. Escherichia coli epitomizes these obst...
pubmed.ncbi.nlm.nih.gov
December 2, 2024 at 6:26 PM
Perhaps in the future we will be able to distinguish colonizing ASB strains from uropathogenic strains of bacteria. 9/n
pubmed.ncbi.nlm.nih.gov/31794727/
pubmed.ncbi.nlm.nih.gov/31794727/
A large cohort study suggests risk of bacteremia from a urinary source in hospitalized pts w/ASB is very low. The decision to treat or not always comes down to the risk-benefit ratio for the pt in question - perhaps these data may help further reframe that risk. 8/n
pubmed.ncbi.nlm.nih.gov/38477915/
pubmed.ncbi.nlm.nih.gov/38477915/
Bacteremia From a Presumed Urinary Source in Hospitalized Adults With Asymptomatic Bacteriuria - PubMed
In patients with ASB, bacteremia from a presumed urinary source was rare, occurring in less than 1% of patients with AMS. A personalized, risk-based approach to empiric therapy could decrease unnecess...
pubmed.ncbi.nlm.nih.gov
December 2, 2024 at 6:26 PM
A large cohort study suggests risk of bacteremia from a urinary source in hospitalized pts w/ASB is very low. The decision to treat or not always comes down to the risk-benefit ratio for the pt in question - perhaps these data may help further reframe that risk. 8/n
pubmed.ncbi.nlm.nih.gov/38477915/
pubmed.ncbi.nlm.nih.gov/38477915/
The corollary to these data are small RCTs that have studied purposeful inoculation of ASB strains into the bladders of those at high risk of recurrent UTIs, like persons with spinal cord injury, with positive findings. 7/n
pubmed.ncbi.nlm.nih.gov/16231269/
pubmed.ncbi.nlm.nih.gov/20483149/
pubmed.ncbi.nlm.nih.gov/16231269/
pubmed.ncbi.nlm.nih.gov/20483149/
Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial - PubMed
This prospective, randomized, placebo-controlled, double-blind pilot trial examined the efficacy of bacterial interference in preventing urinary tract infection (UTI) in 27 patients with spinal cord i...
pubmed.ncbi.nlm.nih.gov
December 2, 2024 at 6:26 PM
The corollary to these data are small RCTs that have studied purposeful inoculation of ASB strains into the bladders of those at high risk of recurrent UTIs, like persons with spinal cord injury, with positive findings. 7/n
pubmed.ncbi.nlm.nih.gov/16231269/
pubmed.ncbi.nlm.nih.gov/20483149/
pubmed.ncbi.nlm.nih.gov/16231269/
pubmed.ncbi.nlm.nih.gov/20483149/
Might this ability of ASB strains to outcompete uropathogens explain the signal in the literature for *increased* risk of symptomatic UTI following ASB treatment? 🤔 6/n
pubmed.ncbi.nlm.nih.gov/22677710/
pubmed.ncbi.nlm.nih.gov/26270684/
pubmed.ncbi.nlm.nih.gov/22677710/
pubmed.ncbi.nlm.nih.gov/26270684/
December 2, 2024 at 6:26 PM
Might this ability of ASB strains to outcompete uropathogens explain the signal in the literature for *increased* risk of symptomatic UTI following ASB treatment? 🤔 6/n
pubmed.ncbi.nlm.nih.gov/22677710/
pubmed.ncbi.nlm.nih.gov/26270684/
pubmed.ncbi.nlm.nih.gov/22677710/
pubmed.ncbi.nlm.nih.gov/26270684/
In fact, the ASB strain E. coli 83972 has been found to outcompete many uropathogens! 🦠 5/n
pubmed.ncbi.nlm.nih.gov/38780216/
pubmed.ncbi.nlm.nih.gov/38780216/
Competitive fitness of asymptomatic bacteriuria E. coli strain 83972 against uropathogens in human urine - PubMed
Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. The main causative agent of UTI is uropathogenic <i>Escherichia coli</i> (UPEC). There is an immediate need for ...
pubmed.ncbi.nlm.nih.gov
December 2, 2024 at 6:26 PM
In fact, the ASB strain E. coli 83972 has been found to outcompete many uropathogens! 🦠 5/n
pubmed.ncbi.nlm.nih.gov/38780216/
pubmed.ncbi.nlm.nih.gov/38780216/
There are well-characterized ASB strains, like E. coli 83972, that lack virulence factors such as adhesins and are distinct from uropathogenic E. coli. 4/n
pubmed.ncbi.nlm.nih.gov/17502385/
pubmed.ncbi.nlm.nih.gov/17502385/
December 2, 2024 at 6:26 PM
There are well-characterized ASB strains, like E. coli 83972, that lack virulence factors such as adhesins and are distinct from uropathogenic E. coli. 4/n
pubmed.ncbi.nlm.nih.gov/17502385/
pubmed.ncbi.nlm.nih.gov/17502385/